The contract manufacturing market for Pharmaceuticals in China
Owing to reasons, such as a booming economy and availability of skilled labor, outsourcing to Asian CMOs, primarily in China, is considered an attractive business model to pharmaceutical developers / sponsors, across the world
Roots Analysis is pleased to
announce the publication of its recent study, titled, “China Pharmaceutical
Contract Manufacturing Services Market, 2020-2030.”
The report features an extensive study of the
current market landscape and future opportunities associated with the
pharmaceutical contract manufacturing market in China. The study also features
a detailed analysis, highlighting the capabilities of pharmaceutical
CMOs in this region. Amongst other elements, the report
features:
§
A detailed assessment
of the current market landscape of pharmaceutical contract manufacturers in
China engaged in the development of active pharmaceutical ingredients (APIs),
intermediates and finished dosage formulations (FDFs).
§
A detailed landscape
of the pharmaceutical manufacturing facilities in China, including an analysis
based on location of these facilities, highlighting key manufacturing hubs.
§
A brief discussion of
various regulatory guidelines in China and various challenges, related to
regulatory scrutiny, faced by pharmaceutical manufacturers in China.
§
Detailed profiles of key
players that offer a diverse range of capabilities for the manufacturing of
pharmaceutical products in China.
§
A review of the pharmaceutical manufacturing
related initiatives of the top 10 big pharma players (shortlisted from the top companies of 2019 by revenues).
§
An analysis of the
partnerships and acquisitions that have been established in this domain, in the
recent past.
§
A detailed capacity
analysis based on the installed reactor capacities of the manufacturing
facilities in China.
§
A case study
comparing the key characteristics of large molecule and small molecule drugs,
along with details on the various steps involved in their respective
manufacturing processes.
§
A detailed market forecast, featuring analysis of the
current and projected future opportunity across key market segments (listed
below)
§
Key Geographical
Regions
- Eastern China
- Southern China
- Northern China
§
Type of Product
- Active
Pharmaceutical Ingredients (APIs)
- Drug Products
§
Type of Drug Product
- Solid
- Liquid / Semi-Solid
- Injectable
- Others
§
Scale of Operation
- Clinical
- Commercial
§
Company Size
- Small
- Mid-Sized
- Large / Very Large
Key
players covered in the https://www.rootsanalysis.com/reports/view_document/china-pharmaceutical-contract-manufacturing/312.html
§
2Y-Chem
§
Aurisco Pharmaceutical
§
ChemPartner
§
Dorrapharma
§
Hubei Biocause Pharmaceutical
§
Infoark
§
Ningbo Menovo Pharmaceutical
§
Shandong Xinhua Pharmaceutical
§
Shanghai Acebright Pharmaceuticals
§
STA Pharmaceutical
§
Zhejiang Huahai Pharmaceutical
For more information please
click on the following link:
Other Recent
Offerings
1.
China
Biopharmaceutical Contract Manufacturing Market, 2020 – 2030
2.
HPAPI
and Cytotoxic Drugs Manufacturing Market (3rd Edition), 2020-2030
3.
Novel
coronavirus (COVID-19): Preventive Vaccines, Therapeutics and Diagnostics in
Development
About Roots Analysis
Roots Analysis is one of the fastest
growing market research companies, sharing fresh and independent perspectives
in the bio-pharmaceutical industry. The in-depth research, analysis and
insights are driven by an experienced leadership team which has gained many
years of significant experience in this sector. If you’d like help with your
growing business needs, get in touch at info@rootsanalysis.com
Contact Information
Roots Analysis Private
Limited
Gaurav Chaudhary
+1 (415) 800 3415
Facebook - https://www.facebook.com/RootsAnalysis
LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
Twitter - https://twitter.com/RootsAnalysis
Medium - https://medium.com/@RootsAnalysis
Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/
Comments
Post a Comment